TTX MC 138
Alternative Names: TTX-MC-138Latest Information Update: 16 Jul 2024
At a glance
- Originator TransCode Therapeutics
- Class Antineoplastics; Antisense oligonucleotides; Immunotherapies
- Mechanism of Action Cell death stimulants; Gene silencing; MicroRNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase 0 Solid tumours
- Preclinical Colorectal cancer; Glioblastoma; Osteosarcoma; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 31 May 2024 Pharmacodynamics, pharmacokinetic and adverse event data from a preclinical trial in Cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Pharmacokinetic and adverse event data from a phase 0 trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 29 May 2024 Efficacy and adverse events data from a phase 0 trial in Solid tumours released by TransCode Therapeutics